Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.845 EUR | +0.60% | -11.05% | +60.95% |
05-14 | Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says | MT |
05-13 | Transcript : DURECT Corporation, Q1 2024 Earnings Call, May 13, 2024 |
Evolution of the average Target Price on DURECT Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering DURECT Corporation
JonesTrading Institutional Services | |
HC Wainwright | |
Cantor Fitzgerald | |
Oppenheimer | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- DRRX Stock
- DC8A Stock
- Consensus DURECT Corporation